Clinical Report: Transcriptomic Analysis of Lacrimal Glands in Sjogren’s Disease

Overview

This study reveals significant alterations in the transcriptomic profiles of lacrimal glands in a Sjogren’s disease mouse model, highlighting key molecular factors associated with glandular inflammation and dysfunction. The findings emphasize the role of immune responses and cytokine activation in the progression of aqueous-deficient dry eye disease.

Background

Sjogren’s disease (SjD) is a chronic autoimmune disorder that primarily affects the lacrimal and salivary glands, leading to dry eye and dry mouth symptoms. Understanding the molecular mechanisms behind lacrimal gland dysfunction is crucial for developing targeted therapies. Current treatments often provide only symptomatic relief, underscoring the need for deeper insights into the pathophysiology of SjD.

Data Highlights

Key Findings

• Increased number of differentially expressed genes correlating with disease progression.
• Significant upregulation of immune response pathways in lacrimal glands.
• Activation of cytokine-mediated inflammatory responses observed.
• Key dysregulated genes were similarly identified in other SjD-related studies.
• Biological processes related to lymphocyte activation and lipid metabolism were notably impacted.

Clinical Implications

The findings suggest that targeting the identified dysregulated pathways and molecules may offer new therapeutic strategies for managing chronic lacrimal gland inflammation and dysfunction in SjD patients. Understanding these molecular changes can enhance the development of more effective treatments beyond symptomatic relief.

Conclusion

This transcriptomic analysis provides valuable insights into the molecular mechanisms of lacrimal gland dysfunction in Sjogren’s disease, highlighting potential targets for future therapeutic interventions.

References

1. Clinical Rheumatology, 2024 -- Discovery and validation of inflammatory markers in primary Sjögren’s syndrome
2. Contact Lens Spectrum, 2021 -- THE SJOGREN'S PARADOX
3. Clinical Rheumatology, 2022 -- Changes in CD8+ T cell populations in the bloodstream and salivary glands of individuals with primary Sjögren’s syndrome
4. Clinical Rheumatology, 2024 -- Metabolomic Profiling of Fecal Samples to Investigate the Influence of Gut Microbiota and Short-Chain Fatty Acids on the Mechanism of Action of Timosaponin AIII in Sjögren’s Syndrome
5. 2016 ACR-EULAR Classification Criteria for primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts - PMC
6. Novartis, 2025 -- ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
7. Pathogenesis of Sjögren's disease: one year in review 2024 - PubMed
8. 2016 ACR-EULAR Classification Criteria for primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts - PMC
9. Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials | Novartis
10. Pathogenesis of Sjögren's disease: one year in review 2024 - PubMed